China Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking towards a 2022 IPO with the aim of becoming a globally competitive player in the bispecific antibody field. The Series C financing round means that the company has raised over USD 220…
China The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in June; the potential of Western China as a manufacturing hub; and EpimAb’s plan for a public stock offering in 2022 amid a booming global bispecific antibodies market. Pharma Not Immune From Coming…
China Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking to crack both the Chinese and international markets. EpimAB Biotherapeutics Founded in 2015, EpimAb Biotherapeutics is a privately owned…
China Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific antibody-generating platform, Fabs-In-Tandem Immunoglobulin (FIT-Ig®) and its ability to discover and generate novel and differentiated bispecific antibodies to meet unmet medical needs in China; shares the progress of their first program, EMB01, a EGFR-cMet bispecific…
See our Cookie Privacy Policy Here